Navigation Links
Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. The clinical study was carried out in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) based at the University of California San Diego (UCSD) and funded by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).  

Forty-nine (49) patients with mild to moderate Alzheimer's disease were treated with CERE-110 at 10 clinical sites throughout the U.S. Approximately half of the patients received CERE-110 while the other half received an appropriate sham (placebo) surgery control treatment. Patients will be followed for a minimum of two years with respect to safety, brain imaging, as well as measures of cognitive function and quality of life. Standard tests used in Alzheimer's clinical trials.

"We are very excited that enrollment in the first blinded study of NGF gene therapy for Alzheimer's disease is now completed and appreciate the courage of all of the patients and their family members that enrolled in this very important study. We also appreciate the efforts of the ADCS and the National Institute on Aging for carrying out and supporting the operational aspects of this study" stated Jeffrey M. Ostrove , Ph.D., president and chief executive officer of Ceregene, Inc., the developer of CERE-110. Dr. Ostrove added "In addition to CERE-110 for Alzheimer's disease, we have also completed enrollment in two controlled Phase 2 clinical trials of CERE-120 for Parkinson's disease. At this time, we would like to recognize the leadership role of Raymond T. Bartus , Ph.D., our chief scientific officer who led the development effor
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
2. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
3. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
4. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
5. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
6. Parkinsons Disease: World Drug Market 2013-2023
7. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
8. Adventrx To Develop ANX-188 For Complications Of Arterial Disease
9. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
10. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
11. Shire Supports Rare Disease Day 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... , May 23, 2013   Direct ... following mastectomy is an appropriate option for many ... to surgically reduce their breast cancer risk, or ... gradual expansion process and a second surgery to ... in the same surgery as mastectomy can be ...
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress Solutions, ... market, announced today the company has signed a letter ... company based in Huntsville, AL . ... in the staffing and recruitment of telemedicine physicians. Consideration ... the final agreement, which is expected by June 30, ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... with Scripps Florida and Scripps Research in La ... ... FRANCISCO, Calif., and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard ... and The Scripps Research,Institute, a non-profit biomedical research organization, today announced,that ...
... DOYLESTOWN, Pa., May 14 The Quigley,Corporation (Nasdaq: ... study,conducted by its wholly owned subsidiary, Quigley Pharma ... anti-viral activity of its compound,QR448(a). The compound was ... Bronchitis Virus (IBV). The data from the study ...
Cached Medicine Technology:Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5
(Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
(Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... 2013 BestSatelliteProviders.com the online satellite ... of consumers compare the features and services offered ... recently released the rankings of the best ... for viewing on their website. , ... to Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When ...
Breaking Medicine News(10 mins):Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... therapy may encourage prostate cancer cells to produce a ... the body, a new study by Johns Hopkins researchers ... to changes in this standard treatment for a sometimes ... discovery is far too preliminary for prostate cancer patients ...
... well as slight changes in eating behavior, could explain ... narcolepsy, according to a study published in the October ... authored by Dorothe Chabas, MD, PhD, of the Fdration ... on 13 patients with narcolepsy and nine healthy controls ...
... studies that have indicated the speed with which adolescents can ... Medical School have conducted the first study to determine why ... not. , We know that nicotine can have an ... that not every adolescent who tries a cigarette gets hooked, ...
... in mice that surgeons and cardiologists may be able ... , The research, published in the October issue of ... the British Heart Foundation and conducted by Saadeh Suleiman, ... and his colleagues at the Bristol Heart Institute. It ...
... suggestion questioned by experts , , SUNDAY, Sept. 30 (HealthDay ... more likely to visit emergency rooms or be hospitalized ... the finding of a new study that reaches the ... may underlie these racial disparities." , However, that genetics ...
... to not stop statin drug use , , ... disease should not stop taking cholesterol-lowering drugs before any ... this week by the American Heart Association and the ... update those published in 2002, provide a framework for ...
Cached Medicine News:Health News:Standard treatment for prostate cancer may encourage spread of disease 2Health News:Lower metabolism, eating behavior possibly explain the cause of overweight in narcolepsy 2Health News:Initial reaction to nicotine can dictate addiction 2Health News:New research suggests hearts are experts at self-preservation 2Health News:Do Blacks Have Genetic Weakness to Asthma? 2Health News:Take Care of Heart Before Any Surgery: Experts 2
Compact tray features all components for urethral catheterization....
Inquire...
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... immunoassay for the quantification of NT-proBNP in ... Elecsys proBNP assay helps to rule-out efficiently ... also indicate the severity of the disease ... addition, NT-proBNP facilitates monitoring, allowing for the ...
Medicine Products: